Redeye: Gasporox - Orders up, but earnings linger for 2024
Redeye states that net sales were slightly higher than expected, but OPEX was also higher. EBITDA was still in line. After a solid 2023, we believe 2024 will be a transitional year with continued net sales growth but higher OPEX. We estimate Gasporox’s order book to be SEK12.6m (35% of 2024e net sales). Redeye lowers its base case, but bull and bear cases remain unchanged.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/